Browsing Tag
Tenax Therapeutics
1 post
TNX-103 Phase 3 failure forces Tenax into FDA reset after nearly 90% stock plunge
TNX-103 misses Phase 3 as Tenax shares crash nearly 90%. A 26.3-meter subgroup benefit now drives the company’s FDA rescue strategy.